We are live on ! Find out more
ASMB icon

Assembly Biosciences

98 hedge funds and large institutions have $204M invested in Assembly Biosciences in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,252% more call options, than puts

Call options by funds: $5.48M | Put options by funds: $126K

0.16% less ownership

Funds ownership: 6.88%6.72% (-0.16%)

8% less funds holding

Funds holding: 10698 (-8)

14% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 37

29% less capital invested

Capital invested by funds: $286M → $204M (-$82.3M)

42% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 19

Holders
98
Holders Change
-8
Holders Change %
-7.55%
% of All Funds
2.15%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
32
Reduced
37
Closed
19
Calls
$5.48M
Puts
$126K
Net Calls
+$5.36M
Net Calls Change
-$2.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Voloridge Investment Management
51
Voloridge Investment Management
Florida
$343K +$228K +1,507 +108%
California State Teachers Retirement System (CalSTRS)
52
California State Teachers Retirement System (CalSTRS)
California
$342K
State of Wisconsin Investment Board
53
State of Wisconsin Investment Board
Wisconsin
$334K -$374K -2,474 -47%
AllianceBernstein
54
AllianceBernstein
Tennessee
$302K +$31.5K +208 +9%
HSBC Holdings
55
HSBC Holdings
United Kingdom
$277K +$355K +2,347 New
WCM
56
Weld Capital Management
New York
$271K +$347K +2,295 New
Bank of America
57
Bank of America
North Carolina
$266K -$28.7K -190 -8%
CSS
58
Cubist Systematic Strategies
Connecticut
$234K -$33.3K -220 -10%
New York State Common Retirement Fund
59
New York State Common Retirement Fund
New York
$229K
SIM
60
Spark Investment Management
New York
$187K
VEA
61
Virtus ETF Advisers
New York
$172K -$12.3K -81 -5%
PPA
62
Parametric Portfolio Associates
Washington
$172K +$19.5K +129 +10%
UBS Group
63
UBS Group
Switzerland
$170K +$154K +1,017 +239%
State Board of Administration of Florida Retirement System
64
State Board of Administration of Florida Retirement System
Florida
$167K +$13.8K +91 +7%
Manulife (Manufacturers Life Insurance)
65
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$161K
AG
66
Algert Global
California
$159K +$33.3K +220 +20%
TRSOTSOK
67
Teachers Retirement System of the State of Kentucky
Kentucky
$143K
AIG
68
American International Group
New York
$140K -$1.36K -9 -0.8%
CS
69
Credit Suisse
Switzerland
$139K -$52.8K -349 -23%
Wells Fargo
70
Wells Fargo
California
$134K +$13K +86 +8%
Jacobs Levy Equity Management
71
Jacobs Levy Equity Management
New Jersey
$131K +$169K +1,114 New
California Public Employees Retirement System
72
California Public Employees Retirement System
California
$115K
JG
73
Jefferies Group
New York
$112K +$144K +951 New
UBS AM
74
UBS AM
Illinois
$110K
Millennium Management
75
Millennium Management
New York
$110K -$2.53M -16,709 -95%

ASMB Hedge Fund Activity: Q3 2019 in Review

98 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2019, worth a combined $204M — down 29% from $286M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ASMB and 11 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 32 added.

The largest buyer was Rock Springs Capital Management, adding an estimated $9.33M. The largest seller was OrbiMed, exiting entirely with an estimated $7.06M sold.

  • 98 institutional investors held Assembly Biosciences (ASMB) as of Q3 2019, down from 106 in Q2 2019.
  • Funds reported $204M of Assembly Biosciences stock for Q3 2019, down 29% quarter-over-quarter.
  • 11 funds opened new Assembly Biosciences positions in Q3 2019 and 19 closed out, a net change of -8 holders.
  • The largest Assembly Biosciences buyer in Q3 2019 was Rock Springs Capital Management, an estimated $9.33M added.
  • The largest Assembly Biosciences seller in Q3 2019 was OrbiMed, an estimated $7.06M sold.

Based on aggregated 13F filings for Q3 2019.